HLA ligandome tumor antigen discovery for personalized vaccine approach.
about
Systems Biology Approach for Cancer Vaccine Development and EvaluationTranslation of genomics-guided RNA-based personalised cancer vaccines: towards the bedsidePeptide-based vaccines for cancer therapyTumor neoantigens: building a framework for personalized cancer immunotherapyMass Spectrometry of Human Leukocyte Antigen Class I Peptidomes Reveals Strong Effects of Protein Abundance and Turnover on Antigen PresentationThermal and mechanical high-intensity focused ultrasound: perspectives on tumor ablation, immune effects and combination strategies.Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia.A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell linesCharacterization of the Canine MHC Class I DLA-88*50101 Peptide Binding Motif as a Prerequisite for Canine T Cell Immunotherapy.Tumor antigen discovery through translation of the cancer genome.Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens.HLA-binding properties of tumor neoepitopes in humans.Antigen-specific vaccines for cancer treatment.Could mycobacterial Hsp70-containing fusion protein lead the way to an affordable therapeutic cancer vaccine?Peptide-based vaccination and induction of CD8+ T-cell responses against tumor antigens in breast cancer.Human Leukocyte Antigen (HLA) Peptides Derived from Tumor Antigens Induced by Inhibition of DNA Methylation for Development of Drug-facilitated Immunotherapy.Immunological landscape and immunotherapy of hepatocellular carcinoma.Understanding dendritic cell immunotherapy in ovarian cancer.Validation of immunomonitoring methods for application in clinical studies: The HLA-peptide multimer staining assay.Sharpening the Edge for Precision Cancer Immunotherapy: Targeting Tumor Antigens through Oncolytic Vaccines.'Hotspots' of Antigen Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen Prioritization.New developments in cancer vaccines.The role of mass spectrometry and proteogenomics in the advancement of HLA epitope prediction.Informatics for cancer immunotherapy.Cancer Immunotherapy Targeted Glypican-3 or Neoantigens.HLA-A24 ligandome analysis of colon and lung cancer cells identifies a novel cancer-testis antigen and a neoantigen that elicits specific and strong CTL responses.Preclinical and clinical development of neoantigen vaccines.Targeting Neoantigens in Glioblastoma: An Overview of Cancer Immunogenomics and Translational Implications.T-Cell Epitope Discovery for Therapeutic Cancer Vaccines.Increasing immunogenicity of cancer vaccines to improve their clinical outcome.Beyond checkpoint inhibition - Immunotherapeutical strategies in combination with radiation.Immunotherapy of hepatocellular carcinomaNeoantigen Vaccine Delivery for Personalized Anticancer ImmunotherapyImmunopeptidomic Profiling of HLA-A2-Positive Triple Negative Breast Cancer Identifies Potential Immunotherapy Target AntigensRNA editing derived epitopes function as cancer antigens to elicit immune responses
P2860
Q26782580-0F338BC1-4558-4B38-A5C7-1D6CFAE6C60FQ27015695-532F5768-1235-47F3-A305-FD24872AB98FQ27022312-E5BE7E31-C369-4DC6-8125-B981CB435CF3Q28082704-5094BBEC-66BB-4B54-9DF3-D086A1BE79D4Q30002365-ABF2D838-4DE7-4C9E-B70D-BAE59B14ABEDQ30363372-16B5A1DC-C125-4B84-A938-9F4D788B9BB3Q33917224-628B5407-08B2-4794-92AF-7D566AF91573Q35626593-A43CEE92-74DC-4A1C-A77F-DAD93527AD9CQ36205561-FA039DB6-C2E6-44E3-8EAD-AF77A09EBC67Q38203472-56C337E8-787B-404A-90DD-960D9ADF9E56Q38212231-7BDF4F8D-6EC7-40CD-86DC-D47C01946F83Q38217357-C825F775-1D47-4205-8B59-3C840FC8FC78Q38284692-ED35ED70-EDF4-45C8-94E4-F99E532FB670Q38286381-D7C16CCE-CF3B-42FD-B4B6-05299E79F195Q38293525-27973CF4-0A28-4169-BEBC-E68EF0C1E1EBQ38390185-A635D1FA-0042-4098-8325-C6E2EDB89D59Q38611895-254FAB03-04C7-43F8-80E2-C9F26D5D5527Q38808249-47654EED-A837-4753-9D9A-05357DB64965Q39641905-87E40D0A-76EA-49A0-93A9-8C8EAC30C617Q40104793-5BFFC0FB-3B59-490B-98FA-CCE8A1A1E70AQ45718710-7126730A-DBBB-4746-B42E-C8E03E81B9A5Q46502445-7897F957-98FC-4E57-8522-DC54351511C3Q47190955-DCF7303D-A64C-437E-9BDF-9C04BA7B5CA1Q47290509-22616B53-176E-4BD1-96E8-BD44B9294246Q47760070-7668515C-BEC5-495C-BEA6-438CD606E179Q47835567-496B87B7-A58A-49B4-8877-5613F43BE167Q49668436-881A2018-C046-4074-AACC-8BF3B6F64623Q50130464-66EDFE6C-1854-4B45-B51D-9A9704153702Q50861629-7A46AA75-AA47-4D57-96CF-75EC18D0B100Q54763767-B8E647CE-ACCD-4766-95A1-0B714785A486Q55316979-447A9C3B-7F7F-417E-915B-7225AA856C36Q56896669-E328D287-B9C7-4E89-8CC1-D351FA89C498Q57177418-5B5F2CC5-9DF1-4E74-94CE-7A1804C29669Q58214193-9DF0D716-AD79-4EE9-9E4A-7A634155827DQ58698657-4BBD7C36-891D-4BA1-9785-6BB2D0FFAF28
P2860
HLA ligandome tumor antigen discovery for personalized vaccine approach.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
HLA ligandome tumor antigen discovery for personalized vaccine approach.
@en
type
label
HLA ligandome tumor antigen discovery for personalized vaccine approach.
@en
prefLabel
HLA ligandome tumor antigen discovery for personalized vaccine approach.
@en
P2860
P1476
HLA ligandome tumor antigen discovery for personalized vaccine approach.
@en
P2093
Harpreet Singh-Jasuja
P2860
P304
P356
10.1586/14760584.2013.836911
P577
2013-10-01T00:00:00Z
2013-10-04T00:00:00Z